WHO and partners have facilitated access to a candidate vaccine and treatments for the outbreak of Sudan #Ebola virus in #Uganda: https://bit.ly/3EjuKc5
The first 2160 doses of the vaccine candidate, and the treatments, are already in Kampala, as they were pre-positioned as part of outbreak preparedness.
The first 2160 doses of the vaccine candidate, and the treatments, are already in Kampala, as they were pre-positioned as part of outbreak preparedness.
World Health Organization
WHO and partners enable access to candidate vaccine and treatments for outbreak of Sudan Ebola virus disease in Uganda
WHO and partners have immediately boosted their support to the Ugandan government’s response to an outbreak of Sudan virus disease outbreak (SVD, part of the Ebola family), including by facilitating access to a candidate vaccine and candidate treatments.
This media is not supported in your browser
VIEW IN TELEGRAM
With WHO's support, Uganda’s Health Ministry has started a vaccine trial against #Ebola Sudan virus today. The trial will enroll contacts of people with the disease, and contacts of the contacts.
This vaccination trial was initiated with record speed, only three days since the outbreak was declared, while ensuring full compliance with international and national regulatory and ethical requirements. It is also the first trial to assess the clinical efficacy of a vaccine against Ebola Sudan virus disease.
This trial demonstrates the importance of investing in R&D for vaccines and treatments and outbreak response preparedness, as well as partnerships. We thank Makerere University and UVRI for their leadership, as well as Africa CDC, CEPI, EU HERA and IDRC for their collaboration on this lifesaving effort.
WHO will continue supporting the government in a comprehensive response to bring the outbreak under control.
This vaccination trial was initiated with record speed, only three days since the outbreak was declared, while ensuring full compliance with international and national regulatory and ethical requirements. It is also the first trial to assess the clinical efficacy of a vaccine against Ebola Sudan virus disease.
This trial demonstrates the importance of investing in R&D for vaccines and treatments and outbreak response preparedness, as well as partnerships. We thank Makerere University and UVRI for their leadership, as well as Africa CDC, CEPI, EU HERA and IDRC for their collaboration on this lifesaving effort.
WHO will continue supporting the government in a comprehensive response to bring the outbreak under control.